Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

547 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Human cytochrome P450 2A13 efficiently metabolizes chemicals in air pollutants: naphthalene, styrene, and toluene.
Fukami T, Katoh M, Yamazaki H, Yokoi T, Nakajima M. Fukami T, et al. Chem Res Toxicol. 2008 Mar;21(3):720-5. doi: 10.1021/tx700325f. Epub 2008 Feb 12. Chem Res Toxicol. 2008. PMID: 18266326
Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted.
Yamanaka H, Nakajima M, Nishimura K, Yoshida R, Fukami T, Katoh M, Yokoi T. Yamanaka H, et al. Among authors: fukami t. Eur J Pharm Sci. 2004 Aug;22(5):419-25. doi: 10.1016/j.ejps.2004.04.012. Eur J Pharm Sci. 2004. PMID: 15265511
A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo.
Fukami T, Nakajima M, Yoshida R, Tsuchiya Y, Fujiki Y, Katoh M, McLeod HL, Yokoi T. Fukami T, et al. Clin Pharmacol Ther. 2004 Dec;76(6):519-27. doi: 10.1016/j.clpt.2004.08.014. Clin Pharmacol Ther. 2004. PMID: 15592323
Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity.
Fukami T, Nakajima M, Higashi E, Yamanaka H, Sakai H, McLeod HL, Yokoi T. Fukami T, et al. Drug Metab Dispos. 2005 Aug;33(8):1202-10. doi: 10.1124/dmd.105.004994. Epub 2005 May 17. Drug Metab Dispos. 2005. PMID: 15900015 Clinical Trial.
A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity.
Fukami T, Nakajima M, Higashi E, Yamanaka H, McLeod HL, Yokoi T. Fukami T, et al. Biochem Pharmacol. 2005 Sep 1;70(5):801-8. doi: 10.1016/j.bcp.2005.05.029. Biochem Pharmacol. 2005. PMID: 15993850
CYP2A6 AND CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions.
Yamanaka H, Nakajima M, Fukami T, Sakai H, Nakamura A, Katoh M, Takamiya M, Aoki Y, Yokoi T. Yamanaka H, et al. Among authors: fukami t. Drug Metab Dispos. 2005 Dec;33(12):1811-8. doi: 10.1124/dmd.105.006254. Epub 2005 Aug 31. Drug Metab Dispos. 2005. PMID: 16135656
Isoflavones inhibit nicotine C-oxidation catalyzed by human CYP2A6.
Nakajima M, Itoh M, Yamanaka H, Fukami T, Tokudome S, Yamamoto Y, Yamamoto H, Yokoi T. Nakajima M, et al. Among authors: fukami t. J Clin Pharmacol. 2006 Mar;46(3):337-44. doi: 10.1177/0091270005285199. J Clin Pharmacol. 2006. PMID: 16490810
Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations.
Nakajima M, Fukami T, Yamanaka H, Higashi E, Sakai H, Yoshida R, Kwon JT, McLeod HL, Yokoi T. Nakajima M, et al. Among authors: fukami t. Clin Pharmacol Ther. 2006 Sep;80(3):282-97. doi: 10.1016/j.clpt.2006.05.012. Clin Pharmacol Ther. 2006. PMID: 16952495 Clinical Trial.
CYP2A13 expressed in human bladder metabolically activates 4-aminobiphenyl.
Nakajima M, Itoh M, Sakai H, Fukami T, Katoh M, Yamazaki H, Kadlubar FF, Imaoka S, Funae Y, Yokoi T. Nakajima M, et al. Among authors: fukami t. Int J Cancer. 2006 Dec 1;119(11):2520-6. doi: 10.1002/ijc.22136. Int J Cancer. 2006. PMID: 16988941
CYP2A13 metabolizes the substrates of human CYP1A2, phenacetin, and theophylline.
Fukami T, Nakajima M, Sakai H, Katoh M, Yokoi T. Fukami T, et al. Drug Metab Dispos. 2007 Mar;35(3):335-9. doi: 10.1124/dmd.106.011064. Epub 2006 Dec 18. Drug Metab Dispos. 2007. PMID: 17178771
547 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback